SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

Connect Biopharma Doses First Patient in Mid-Stage Trial of Asthma Drug Candidate

05/12/2021 04:45

08:32 AM EDT, 05/12/2021 (MT Newswires) -- Connect Biopharma Holdings (CNTB) said Wednesday it has dosed the first patient in a phase 2 trial of CBP-201 in adults with moderate-to-severe persistent asthma.

The trial, which is expected to enroll about 300 patients, will assess the efficacy and safety of two doses of the drug candidate.

Price: 14.42, Change: -0.85, Percent Change: -5.57